Finance

Biotechnology company reports fiscal 2005 second quarter results

Published in Gene Therapy Weekly, March 10th, 2005

Neurobiological Technologies, Inc., (NTI) (NASDAQ:NTII) announced a net loss of $2,675,000, or $0.10 per basic and diluted share, for its quarter ended December 31, 2004.

This compares with a net loss of $1,059,000, or $0.06 per basic and diluted share, for the same quarter 1 year ago.

"We are pleased at the progress made since the start of the last quarter and shortly after," stated Paul E. Freiman, president and chief executive officer. "Viprinex (ancrod), a late-stage reperfusion therapy for use in the treatment of ischemic stroke, received fast-track status from the U. S. Food and Drug Administration, a significant step forward in our pivotal...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2005-03-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry